DR.

REDDY'S LABORATORIES LIMITED PART I : STATEMENT OF STANDALONE AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2012 All amounts in Indian Rupees lakhs, except share data Year ended 31.03.11 31.03.12 31.03.11 (Audited) (Audited) (Audited)

Sl. No.

PARTICULARS

31.03.12 (Audited)

Quarter ended 31.12.11 (Unaudited)

Income from operations a) Net sales / income from operations (Net of excise duty) b) License fees and service income c) Other operating income Total income from operations (net)

1,74,871 1,667 2,292 1,78,830

1,56,680 2,159 1,930 1,60,769

1,31,871 1,045 1,750 1,34,666

6,60,378 6,399 7,193 6,73,970

5,21,804 3,103 5,534 5,30,441

Expenses a) Cost of materials consumed b) Purchase of stock-in-trade c) Changes in inventories of finished goods, work-in-progress and stock-ind) Research and development expenses, net e) Employee benefits expense f) Selling expenses g) Provision for decline in the value of long-term investments, net h) Other expenditure i) Depreciation and amortisation Total expenses

52,603 8,530 462 16,744 23,596 14,502 19,248 23,885 8,395 1,67,965 10,865 26,288 37,153 1,567 35,586 35,586 14,407 21,179 21,179 8,478

42,708 7,236 (5,582) 14,947 20,666 19,585 40,492 7,488 1,47,540 13,229 2,417 15,646 1,693 13,953 13,953 3,150 10,803 10,803 8,476

34,220 9,272 58 16,153 18,897 11,171 5,574 16,029 6,550 1,17,924 16,742 2,911 19,653 425 19,228 19,228 2,641 16,587 16,587 8,463

1,79,201 30,763 (10,476) 58,129 86,614 62,506 19,248 93,768 30,115 5,49,868 1,24,102 8,178 1,32,280 6,362 1,25,918 1,25,918 34,682 91,236 91,236 8,478 1,52,811 6,54,653 8,664

1,39,676 33,104 (7,899) 51,286 70,113 47,713 5,574 72,321 24,794 4,36,682 93,759 11,960 1,05,719 538 1,05,181 1,05,181 15,850 89,331 89,331 8,463 1,43,880 5,93,352 185

3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Profit from operations before other income, finance costs and Other income Profit from ordinary activites before finance costs and exceptional items Finance costs Profit from ordinary activities after finance costs but before exceptional Exceptional items Profit from ordinary activities before tax (7 - 8) Tax expense Net Profit from ordinary activities after tax (9 - 10) Extra-ordinary items Net profit for the period / year (11 - 12) Paid - up equity share capital (face value Rs.5/- each) Paid up debt capital Reserves (excluding revaluation reserve and debenture redemption reserve) Debenture redemption reserve Earnings per share for the period (in Rupees) per Rs.5/- share a) Before Extra-ordinary items - Basic - Diluted b) After Extra-ordinary items - Basic - Diluted

12.49 12.43

6.37 6.34

9.80 9.75

53.83 53.56

52.82 52.51

12.49 12.43 (Not annualised)

6.37 6.34 (Not annualised)

9.80 9.75 (Not annualised)

53.83 53.56

52.82 52.51

19

a) Debt equity ratio b) Debt service coverage ratio c) Interest service coverage ratio See accompanying notes to the financial results

0.077 0.606 18.154

0.085 0.929 107.580

DR. REDDY'S LABORATORIES LIMITED PART II : SELECTED INFORMATION FOR THE QUARTER AND YEAR ENDED 31 MARCH 2012 A PARTICULARS OF SHAREHOLDING PARTICULARS 1 Public share holding* - Number of shares (Face value Rs.5/- each) - Percentage of share holding Promoters and promoter group Shareholding a) Pledged/Encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) Quarter ended 31.12.11 Year ended 31.03.11 31.03.12 31.03.11

31.03.12

9,76,27,569 57.57

9,65,43,537 56.94

9,41,24,752 55.61

9,76,27,569 57.57

9,41,24,752 55.61

21,00,000 4.84 1.24

21,00,000 4.84 1.24

b) Non-encumbered - Number of shares 4,34,17,812 4,34,17,812 4,13,17,812 4,34,17,812 - Percentage of shares (as a % of the total shareholding 100.00 100.00 95.16 100.00 of promoter and promoter group) - Percentage of shares (as a % of the total share capital 25.61 25.61 24.41 25.61 of the company) *Public Share Holding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders) B INVESTOR COMPLAINTS Pending at the beginning of the quarter Received during the quarter Disposed of during the quarter Remaining unresolved at the end of the quarter Segment Information Sl. No. PARTICULARS Segment wise revenue, results and capital employed: Segment revenue : a) Pharmaceutical Services and Active Ingredients b) Global Generics c) Proprietary Products Total Less: Inter segment revenue Add : Other unallocable Income Total income 2 Segment results : Profit / (loss) before tax and interest from each segment a) Pharmaceutical Services and Active Ingredients b) Global Generics c) Proprietary Products Total Less: (i) Interest (ii) Other un-allocable expenditure, net Total profit before tax 3 Capital Employed : a) Pharmaceutical Services and Active Ingredients b) Global Generics c) Proprietary Products d) Unallocated Total 31.03.12 (Audited) Quarter ended 31.12.11 (Unaudited) 1 4 5 Nil

4,13,17,812 95.16 24.41

All amounts in Indian Rupees lakhs, except share data Year ended 31.03.11 31.03.12 31.03.11 (Audited) (Audited) (Audited)

79,855 1,16,564 59 1,96,478 17,694 26,334 2,05,118

63,092 1,11,603 44 1,74,739 13,936 2,383 1,63,186

56,592 85,739 50 1,42,381 7,873 3,069 1,37,577

2,59,069 4,68,035 189 7,27,293 53,364 8,219 6,82,148

2,05,467 3,56,227 252 5,61,946 31,551 12,006 5,42,401

15,486 24,679 (4,489) 35,676 1,567 (1,477) 35,586

17,172 33,579 (5,301) 45,450 1,693 29,804 13,953

10,561 15,764 (3,875) 22,450 425 2,797 19,228

48,602 1,57,976 (16,800) 1,89,778 6,362 57,498 1,25,918

30,997 96,210 (11,693) 1,15,514 538 9,795 1,05,181

2,03,180 2,72,931 (1,754) 1,97,438 6,71,795

2,00,208 2,85,365 (3,386) 1,90,191 6,72,378

1,77,497 2,65,407 303 1,58,793 6,02,000

2,03,180 2,72,931 (1,754) 1,97,438 6,71,795

1,77,497 2,65,407 303 1,58,793 6,02,000

DR. REDDY'S LABORATORIES LIMITED Notes:

1 The audited results have been reviewed by the Audit Committee of the Board on 10 May 2012 and approved by the Board of Directors of the Company at their meeting held on 11 May 2 The results for the quarter and nine months ended 31 December 2011 have been subjected to a Limited review by the Statutory Auditors of the Company. An unqualified report has been 2 Statement of assets and liabilities Sl. No. A 1 EQUITY AND LIABILITIES Shareholders Funds a) Share capital b) Reserves and surplus Sub-total - Shareholders' funds Share Application money pending allotment Non-current liabilities a) Long-term borrowings b) Deferred tax liabilities (net) c) Other long-term liabilities d) Long-term provisions Sub-total - Non current liabilities Current Liabilities a) Short-term borrowings b) Trade payables c) Other current liabilities d) Short-term provisions Sub-total - Current liabilities TOTAL - EQUITY AND LIABILITIES B 1 ASSETS Non-current Assets a) Fixed Assets b) Non-current investments c) Long-term loans and advances Sub-total - Non-current assets Current Assets a) Current investments b) Inventories c) Trade receivables d) Cash and cash equivalents e) Short-term loans and advances f) Other current assets Sub-total - Current assets TOTAL - ASSETS 3 Ratios have been computed as follows: a) Debt Equity Ratio= Debt / Net Worth [ Debt: Long Term Borrowings (Current and Non current portions) ] [ Net Worth: Share Capital + Reserves and Surplus ] b) Debt Service Coverage Ratio = Earnings before interest and tax / (Interest expense during the period + Principal repayment for all the loan funds during the period) c) Interest Service Coverage Ratio = Earnings before interest and tax / Interest expense during the period [ Earnings before interest and tax: Profit from ordinary activities before tax + Interest expense] 4 During the year, there have been certain significant changes in the German generics market which are likely to cause an adverse impact on the price realization of some of the company's 5 The Board of Directors at their meeting held on 11 May 2012 have recommended a final dividend of Rs. 13.75 per share subject to approval of shareholders. 6 The figures of the last quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the third quarter of the relevant 7 The figures of the earlier periods have been re-grouped to be in confirmity with the new format prescribed under Clause 41 of the listing agreement. PARTICULARS All amounts in Indian Rupees lakhs, except share data As at As at 31.03.12 31.03.11 (Audited) (Audited)

8,478 6,63,317 6,71,795 51,301 2,003 632 2,120 56,056

8,463 5,93,537 6,02,000 51,300 10,076 602 1,966 63,944

2 2

1,02,036 73,342 98,437 32,398 3,06,213 10,34,064

93,110 80,689 58,895 27,679 2,60,373 9,26,317

2,51,439 2,27,049 63,192 5,41,680

2,23,688 2,46,181 91,170 5,61,039

20,702 1,32,662 1,94,345 84,904 52,993 6,778 4,92,384 10,34,064

1,06,317 1,77,051 6,624 57,784 17,502 3,65,278 9,26,317

By order of the Board For Dr. Reddy's Laboratories Limited

Place: Hyderabad Date: 11 May 2012

Satish Reddy Managing Director & Chief Operating Officer